Alpha Cognition Inc. (ACOG) Stock Price, Financials & Summary

Price chart

Sep 21Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20

Key dataOct 20, 2026

Open$8.57

From 52W high−11.69%

Volume97851.00

Market cap$187.51M

P/E (TTM)—

P/S (TTM)12.3x

Div yield—

Key dataOct 20, 2026

Open

$8.57

From 52W high

−11.69%

Volume

97851.00

Market cap

$187.51M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.3x

P/E (TTM)

—

RSI (14)

49.0

MomentumView details →

1D Return

+1.29%

YTD Return

+34.46%

SummaryUpdated Jun 1, 2026

Alpha Cognition Inc. (NASDAQ:ACOG) is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Vancouver, Canada. The company was formerly known as Crystal Bridge Enterprises Inc. before changing its name in March 2021. Alpha Cognition focuses on developing treatments for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company successfully transitioned from a pre-revenue clinical-stage entity to a commercial-stage company in 2025 with the launch of its flagship product ZUNVEYL for treating mild-to-moderate Alzheimer's disease.

Ask drillr about Alpha Cognition Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−5.3x

EV/Sales

9.6x

P/S (TTM)

12.3x

P/B (TTM)

3.5x

ProfitabilityView details →

Gross Margin

89.89%

Net Margin

−153.61%

EBITDA Margin

−180.15%

ROE (TTM)

−44.26%

ROA (TTM)

−36.33%

Asset Turnover

0.23x

GrowthView details →

Revenue YoY

+232.74%

EPS YoY

+31.77%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+42.08%

EBITDA YoY

−82.49%

MomentumView details →

1D Return

+1.29%

YTD Return

+34.46%

1Y Return

+27.59%

RSI (14)

49.0

vs 50D SMA

−2.56%

vs 200D SMA

+23.92%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

9.03x

Quick Ratio

8.04x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.40

EPS Surprise

−2.00%

Beats (12Q)

4/12

Next Q EPS Est

−$0.28

Avg Surprise (4Q)

6.72%

Rev Surprise

36.86%

Financials snapshotView financials →

Revenue (TTM)

15.26M

Net Income (TTM)

−23.44M

Op. CF (TTM)

−30.91M

Next earningsNov 12, 2026 →

Latest newsMore news →

The United States Patent and Trademark Office published Alpha Cognition’s patent application for a process to prepare benzgalantamine and its salts.7d ago

Alpha Cognition Inc. announced initial results from the CONVERGE real-world evidence evaluation of ZUNVEYL (benzgalantamine) use in long-term care, focusing on 180-day titration and concomitant medication patterns.19d ago

Similar companies

Newbury Street II Acquisition CorpNTWOU Apogee Acquisition Corp UnitsAACPU BRC Group Holdings, Inc.RILY JAB Acquisition Corp. I Units Cons of 1 Sh -A- + 1 Red Wt + 1 RtATLQU Breeze Acquisition Corp. IIBREZ Ampercap Acquisition Co.APMC Find similar companies →

Latest newsMore news →

The United States Patent and Trademark Office published Alpha Cognition’s patent application for a process to prepare benzgalantamine and its salts.7d ago Alpha Cognition Inc. announced initial results from the CONVERGE real-world evidence evaluation of ZUNVEYL (benzgalantamine) use in long-term care, focusing on 180-day titration and concomitant medication patterns.19d ago Saudi Minister Abdullah Alswaha met with Cognition AI Co-Founder and CEO Scott Wu to discuss expanding use of autonomous software engineering solutions and deploying Devin and software agents through HUMAIN's computing capabilities.41d ago